Amedeo Smart

Free Medical Literature Service


 

Amedeo

Bladder Cancer

  Free Subscription

14.06.2021

1 Acta Med Acad
1 Aging Dis
1 Am J Ind Med
1 Am Soc Clin Oncol Educ Book
1 Anal Biochem
1 Anticancer Res
2 Arch Esp Urol
1 BMC Bioinformatics
4 BMC Cancer
1 BMC Urol
1 Cancer Cell Int
1 Cancer Control
1 Cancer Manag Res
3 Cancer Med
1 Cancer Rep (Hoboken)
1 Cancer Treat Rev
6 Cancers (Basel)
1 Cells
1 Chin Med J (Engl)
1 Clin Adv Hematol Oncol
1 Clin Transplant
1 Cureus
6 Curr Urol
1 Diagnostics (Basel)
1 Drug Dev Res
1 Eur J Cancer Prev
2 Eur Urol
1 Eur Urol Focus
2 Eur Urol Oncol
2 Exp Ther Med
2 Front Mol Biosci
5 Front Oncol
1 Front Surg
1 Hinyokika Kiyo
1 Int J Clin Exp Pathol
1 Int J Environ Res Public Health
1 Int J Mol Sci
1 Investig Clin Urol
1 J Biochem Mol Toxicol
1 J Bone Jt Infect
1 J BUON
1 J Cancer Res Clin Oncol
1 J Clin Neurosci
1 J Endourol
1 J Exp Clin Cancer Res
1 J Magn Reson Imaging
1 J Manag Care Spec Pharm
1 J Nanosci Nanotechnol
1 J Natl Cancer Inst
1 J Pers Med
1 J Urol
1 J Vasc Surg Cases Innov Tech
1 JCO Clin Cancer Inform
1 Jpn J Clin Oncol
1 Lancet Oncol
1 Mol Biol Rep
1 Nat Commun
1 Oncoimmunology
1 Sci Rep
4 Urol Oncol
1 Urologia
1 Vaccines (Basel)



    Acta Med Acad

  1. ULAMEC M, Murgic J, Novosel L, Tomic M, et al
    New Insights into the Diagnosis, Molecular Taxonomy, and Treatment of Bladder Cancer.
    Acta Med Acad. 2021;50:143-156.
    >> Share


    Aging Dis

  2. SHIH KW, Chen WC, Chang CH, Tai TE, et al
    Non-Muscular Invasive Bladder Cancer: Re-envisioning Therapeutic Journey from Traditional to Regenerative Interventions.
    Aging Dis. 2021;12:868-885.
    >> Share


    Am J Ind Med

  3. PARK RM, Carreon T, Hanley KW
    Risk assessment for o-toluidine and bladder cancer incidence.
    Am J Ind Med. 2021 Jun 10. doi: 10.1002/ajim.23265.
    >> Share


    Am Soc Clin Oncol Educ Book

  4. HOFFMAN-CENSITS J, Kanesvaran R, Bangs R, Fashoyin-Aje L, et al
    Breaking Barriers: Addressing Issues of Inequality in Trial Enrollment and Clinical Outcomes for Patients With Kidney and Bladder Cancer.
    Am Soc Clin Oncol Educ Book. 2021;41:e174-e181.
    >> Share


    Anal Biochem

  5. ISLAM MK, Syed P, Dhondt B, Gidwani K, et al
    Detection of Bladder Cancer with Aberrantly Fucosylated ITGA3.
    Anal Biochem. 2021 Jun 5:114283. doi: 10.1016/j.ab.2021.114283.
    >> Share


    Anticancer Res

  6. OKUBO K, Isono M, Asano T, REssING N, et al
    Ubiquitin-proteasome System Is a Promising Target for Killing Cisplatin-resistant Bladder Cancer Cells.
    Anticancer Res. 2021;41:2901-2912.
    >> Share


    Arch Esp Urol

  7. AIZCORBE GOMEZ M, Gutierrez Zurimendi G, Arruza Echevarria A
    [Clinicopathologic analysis of 5 cases of urachal adenocarcinoma.]
    Arch Esp Urol. 2021;74:535-540.
    >> Share

  8. SANCHEZ VERDES P, Fernandez-Pello S, Gonzalez Rodriguez I, Salgado Plonski JJ, et al
    [Gross hematuria and usefulness of urinary cytology: Experience at hematuria one stop clinic.]
    Arch Esp Urol. 2021;74:470-476.
    >> Share


    BMC Bioinformatics

  9. LIN JY, Juo BR, Yeh YH, Fu SH, et al
    Putative markers for the detection of early-stage bladder cancer selected by urine metabolomics.
    BMC Bioinformatics. 2021;22:305.
    >> Share


    BMC Cancer

  10. CHEN X, Lin X, Pang G, Deng J, et al
    Significance of KDM6A mutation in bladder cancer immune escape.
    BMC Cancer. 2021;21:635.
    >> Share

  11. RIPOLL J, Ramos M, Montano J, Pons J, et al
    Cancer-specific survival by stage of bladder cancer and factors collected by Mallorca Cancer Registry associated to survival.
    BMC Cancer. 2021;21:676.
    >> Share

  12. LYU X, Wang P, Qiao Q, Jiang Y, et al
    Genomic stratification based on microenvironment immune types and PD-L1 for tailoring therapeutic strategies in bladder cancer.
    BMC Cancer. 2021;21:646.
    >> Share

  13. WANG Z, Tu L, Chen M, Tong S, et al
    Identification of a tumor microenvironment-related seven-gene signature for predicting prognosis in bladder cancer.
    BMC Cancer. 2021;21:692.
    >> Share


    BMC Urol

  14. WU H, Jiang W, Ji G, Xu R, et al
    Exploring microRNA target genes and identifying hub genes in bladder cancer based on bioinformatic analysis.
    BMC Urol. 2021;21:90.
    >> Share


    Cancer Cell Int

  15. DU Y, Jiang X, Wang B, Cao J, et al
    The cancer-associated fibroblasts related gene CALD1 is a prognostic biomarker and correlated with immune infiltration in bladder cancer.
    Cancer Cell Int. 2021;21:283.
    >> Share


    Cancer Control

  16. HUANG J, Zhao L, Wang K, Sun J, et al
    Controlling Nutritional Status Score Evaluates Prognosis in Patients With Non-Muscle Invasive Bladder Cancer.
    Cancer Control. 2021;28:10732748211021078.
    >> Share


    Cancer Manag Res

  17. HAN X, Liu J, Liu Y, Mou L, et al
    LINC-PINT Inhibited Malignant Progression of Bladder Cancer by Targeting miR-155-5p.
    Cancer Manag Res. 2021;13:4393-4401.
    >> Share


    Cancer Med

  18. HEKTOEN HH, Robsahm TE, Stenehjem JS, Axcrona K, et al
    Vitamin D and Vitamin D-binding protein and risk of bladder cancer: A nested case-control study in the Norwegian Janus Serum Bank Cohort.
    Cancer Med. 2021 Jun 3. doi: 10.1002/cam4.3960.
    >> Share

  19. ZUO Y, Xu X, Chen M, Qi L, et al
    The oncogenic role of the cerebral endothelial cell adhesion molecule (CERCAM) in bladder cancer cells in vitro and in vivo.
    Cancer Med. 2021 Jun 8. doi: 10.1002/cam4.3955.
    >> Share

  20. VELMAHOS CS, Badgeley M, Lo YC
    Using deep learning to identify bladder cancers with FGFR-activating mutations from histology images.
    Cancer Med. 2021 Jun 10. doi: 10.1002/cam4.4044.
    >> Share


    Cancer Rep (Hoboken)

  21. PHAM QT, Taniyama D, Akabane S, Harada K, et al
    TDO2 overexpression correlates with poor prognosis, cancer stemness, and resistance to cetuximab in bladder cancer.
    Cancer Rep (Hoboken). 2021 Jun 7:e1417. doi: 10.1002/cnr2.1417.
    >> Share


    Cancer Treat Rev

  22. GRIVAS P, Agarwal N, Pal S, Kalebasty AR, et al
    Avelumab first-line maintenance in locally advanced or metastatic urothelial carcinoma: Applying clinical trial findings to clinical practice.
    Cancer Treat Rev. 2021;97:102187.
    >> Share


    Cancers (Basel)

  23. MIYAKE M, Nishimura N, Iida K, Fujii T, et al
    Intravesical Bacillus Calmette-Guerin Treatment for T1 High-Grade Non-Muscle Invasive Bladder Cancer with Divergent Differentiation or Variant Morphologies.
    Cancers (Basel). 2021;13.
    >> Share

  24. LORAS A, Segovia C, Ruiz-Cerda JL
    Epigenomic and Metabolomic Integration Reveals Dynamic Metabolic Regulation in Bladder Cancer.
    Cancers (Basel). 2021;13.
    >> Share

  25. ZHAO Z, Wang Y, Zhang JJ, Huang XY, et al
    Fascin Inhibitors Decrease Cell Migration and Adhesion While Increase Overall Survival of Mice Bearing Bladder Cancers.
    Cancers (Basel). 2021;13.
    >> Share

  26. PONES M, D'Andrea D, Mori K, Abufraj M, et al
    Differential Prognosis and Response of Denovo vs. Secondary Muscle-Invasive Bladder Cancer: An Updated Systematic Review and Meta-Analysis.
    Cancers (Basel). 2021;13.
    >> Share

  27. BARANI M, Hosseinikhah SM, Rahdar A, Farhoudi L, et al
    Nanotechnology in Bladder Cancer: Diagnosis and Treatment.
    Cancers (Basel). 2021;13.
    >> Share

  28. CANNON-ALBRIGHT LA, Teerlink CC, Stevens J, Huang FW, et al
    A Rare Variant in ERF (rs144812092) Predisposes to Prostate and Bladder Cancers in an Extended Pedigree.
    Cancers (Basel). 2021;13.
    >> Share


    Cells

  29. IDE H, Miyamoto H
    Sex Hormone Receptor Signaling in Bladder Cancer: A Potential Target for Enhancing the Efficacy of Conventional Non-Surgical Therapy.
    Cells. 2021;10.
    >> Share


    Chin Med J (Engl)

  30. ZHENG XN, Qiu S, Tang LS, Ai JZ, et al
    Tumor microenvironment-based drug discovery: a novel insight into bladder cancer immunotherapy.
    Chin Med J (Engl). 2021 Jun 2. pii: 00029330-900000000-98594.
    >> Share


    Clin Adv Hematol Oncol

  31. ROSENBERG JE
    New treatments for patients with progressive metastatic urothelial carcinoma.
    Clin Adv Hematol Oncol. 2021;19:180-183.
    >> Share


    Clin Transplant

  32. ALKASSIS M, Abi Tayeh G, Khalil N, Mansour R, et al
    The Safety and Efficacy of Bacillus Calmette-Guerin Intravesical Therapy in Kidney Transplant Recipients with Superficial Bladder Cancer.
    Clin Transplant. 2021 May 29:e14377. doi: 10.1111/ctr.14377.
    >> Share


    Cureus

  33. GUPTA S, Singh B, Bhatt H, Singh S, et al
    A Case of Systemic Toxicity Related to Intravesical Bacillus Calmette-Guerin for the Treatment of Bladder Cancer.
    Cureus. 2021;13:e15321.
    >> Share


    Curr Urol

  34. MOHAMED DO, Sayed MM, Abdelkawi IF, Elshoieby MH, et al
    Bladder preservation versus radical cystectomy in transitional cell carcinoma and squamous cell carcinoma muscle invasive bladder cancer.
    Curr Urol. 2021;15:11-15.
    >> Share

  35. SHANTHARAM G, Amin A, Pereira J, Kott O, et al
    Intravesical docetaxel for high-risk non-muscle invasive bladder cancer after Bacillus Calmette-Guerin failure.
    Curr Urol. 2021;15:33-38.
    >> Share

  36. SCIARRA A, Di Lascio G, Del Giudice F, Leoncini PP, et al
    Comparison of the clinical usefulness of different urinary tests for the initial detection of bladder cancer: a systematic review.
    Curr Urol. 2021;15:22-32.
    >> Share

  37. MATSUOKA Y, Taoka R, Kohashiguchi K, Tohi Y, et al
    Efficacy and toxicity of intravesical Bacillus Calmette-Guerin therapy in elderly patients with non-muscle-invasive bladder cancer.
    Curr Urol. 2021;15:16-21.
    >> Share

  38. QI Y, Tang D
    Commentary: Bladder cancer.
    Curr Urol. 2021;15:1.
    >> Share

  39. EL KHATIB S
    In vivo photobleaching kinetics and epithelial biodistribution of hexylaminolevulinate-induced protoporphyrin IX in rat bladder cancer.
    Curr Urol. 2021;15:2-10.
    >> Share


    Diagnostics (Basel)

  40. CUCCURULLO V, Di Stasio GD, Manti F, Arcuri P, et al
    The Role of Molecular Imaging in a Muscle-Invasive Bladder Cancer Patient: A Narrative Review in the Era of Multimodality Treatment.
    Diagnostics (Basel). 2021;11.
    >> Share


    Drug Dev Res

  41. YE W, Chen L, Feng C, Liang T, et al
    CircMYLK promotes the growth, migration, invasion, and survival of bladder cancer cells by upregulating CCND3 level via competitively binding to miR-34a.
    Drug Dev Res. 2021 May 30. doi: 10.1002/ddr.21835.
    >> Share


    Eur J Cancer Prev

  42. HEMMINKI K, Forsti A, Hemminki A, Ljungberg B, et al
    Incidence trends in lung and bladder cancers in the Nordic Countries before and after the smoking epidemic.
    Eur J Cancer Prev. 2021 Jun 1. pii: 00008469-900000000-99039.
    >> Share


    Eur Urol

  43. HUSSAIN SA, Porta N, Hall E, Qureshi M, et al
    Reply to Santhanam Sundar and Paul Symonds' Letter to the Editor re: Syed A. Hussain, Nuria Porta, Emma Hall, et al. Outcomes in Patients with Muscle-invasive Bladder Cancer Treated with Neoadjuvant Chemotherapy Followed by (Chemo)radiotherapy in the
    Eur Urol. 2021 May 27. pii: S0302-2838(21)00347.
    >> Share

  44. PEDERZOLI F, Bandini M, Raggi D, Marandino L, et al
    Is There a Detrimental Effect of Antibiotic Therapy in Patients with Muscle-invasive Bladder Cancer Treated with Neoadjuvant Pembrolizumab?
    Eur Urol. 2021 May 27. pii: S0302-2838(21)00387.
    >> Share


    Eur Urol Focus

  45. KOZIKOWSKI M, Suarez-Ibarrola R, Osiecki R, Bilski K, et al
    Role of Radiomics in the Prediction of Muscle-invasive Bladder Cancer: A Systematic Review and Meta-analysis.
    Eur Urol Focus. 2021 Jun 4. pii: S2405-4569(21)00157.
    >> Share


    Eur Urol Oncol

  46. CONTIERI R, Paciotti M, Lughezzani G, Buffi NM, et al
    Long-term Follow-up and Factors Associated with Active Surveillance Failure for Patients with Non-muscle-invasive Bladder Cancer: The Bladder Cancer Italian Active Surveillance (BIAS) Experience.
    Eur Urol Oncol. 2021 May 28. pii: S2588-9311(21)00108.
    >> Share

  47. JOBCZYK M, Stawiski K, Kaszkowiak M, Rajwa P, et al
    Deep Learning-based Recalibration of the CUETO and EORTC Prediction Tools for Recurrence and Progression of Non-muscle-invasive Bladder Cancer.
    Eur Urol Oncol. 2021 Jun 3. pii: S2588-9311(21)00112.
    >> Share


    Exp Ther Med

  48. BRATU O, Marcu D, Anghel R, Spinu D, et al
    Tumoral markers in bladder cancer (Review).
    Exp Ther Med. 2021;22:773.
    >> Share

  49. CHAO Y, Ou Q, Shang J
    Expression and prognostic value of SULT1A2 in bladder cancer.
    Exp Ther Med. 2021;22:779.
    >> Share


    Front Mol Biosci

  50. SEGATTO NV, Bender CB, Seixas FK, Schachtschneider K, et al
    Perspective: Humanized Pig Models of Bladder Cancer.
    Front Mol Biosci. 2021;8:681044.
    >> Share

  51. LIU J, Ma H, Meng L, Liu X, et al
    Construction and External Validation of a Ferroptosis-Related Gene Signature of Predictive Value for the Overall Survival in Bladder Cancer.
    Front Mol Biosci. 2021;8:675651.
    >> Share


    Front Oncol

  52. JIANG LR, Zhang N, Chen ST, He J, et al
    PD-1-Positive Tumor-Associated Macrophages Define Poor Clinical Outcomes in Patients With Muscle Invasive Bladder Cancer Through Potential CD68/PD-1 Complex Interactions.
    Front Oncol. 2021;11:679928.
    >> Share

  53. ZHENG Z, Xu F, Gu Z, Yan Y, et al
    Combining Multiparametric MRI Radiomics Signature With the Vesical Imaging-Reporting and Data System (VI-RADS) Score to Preoperatively Differentiate Muscle Invasion of Bladder Cancer.
    Front Oncol. 2021;11:619893.
    >> Share

  54. EPAILLARD N, Parent P, Loriot Y, Lavaud P, et al
    Treatments Outcomes in Histological Variants and Non-Urothelial Bladder Cancer: Results of a Multicenter Retrospective Study.
    Front Oncol. 2021;11:671969.
    >> Share

  55. GUO C, Li X, Xie J, Liu D, et al
    Long Noncoding RNA SNHG1 Activates Autophagy and Promotes Cell Invasion in Bladder Cancer.
    Front Oncol. 2021;11:660551.
    >> Share

  56. LI Y, Sun L, Guo X, Mo N, et al
    Frontiers in Bladder Cancer Genomic Research.
    Front Oncol. 2021;11:670729.
    >> Share


    Front Surg

  57. CHAI CA, Yeoh WS, Rajandram R, Aung KP, et al
    Comparing CxBladder to Urine Cytology as Adjunct to Cystoscopy in Surveillance of Non-muscle Invasive Bladder Cancer-A Pilot Study.
    Front Surg. 2021;8:659292.
    >> Share


    Hinyokika Kiyo

  58. SASAKI Y, Kadoriku F, Fukatani Y, Yamamoto H, et al
    [A Case of Robot-Assisted Radical Cystoprostatectomy for Locally Advanced Prostate Cancer with Bladder Infiltration].
    Hinyokika Kiyo. 2021;67:163-166.
    >> Share


    Int J Clin Exp Pathol

  59. LIU Z, Liu X, Cai R, Liu M, et al
    Identification of a tumor microenvironment-associated prognostic gene signature in bladder cancer by integrated bioinformatic analysis.
    Int J Clin Exp Pathol. 2021;14:551-566.
    >> Share


    Int J Environ Res Public Health

  60. NIK AB KADIR MN, Mohd Hairon S, Yaacob NM, Ab Manan A, et al
    Survival and Characteristics of Bladder Cancer: Analysis of the Malaysian National Cancer Registry.
    Int J Environ Res Public Health. 2021;18.
    >> Share


    Int J Mol Sci

  61. SCHNEIDER L, Liu J, Zhang C, Azoitei A, et al
    The Role of Interleukin-1-Receptor-Antagonist in Bladder Cancer Cell Migration and Invasion.
    Int J Mol Sci. 2021;22.
    >> Share


    Investig Clin Urol

  62. KIM HS, Seo HK
    Emerging treatments for bacillus Calmette-Guerin-unresponsive non-muscle-invasive bladder cancer.
    Investig Clin Urol. 2021 May 27. pii: 62.e49. doi: 10.4111/icu.20200602.
    >> Share


    J Biochem Mol Toxicol

  63. ZHAO X, Li G, Chong T, Xue L, et al
    TMEM88 exhibits an antiproliferative and anti-invasive effect in bladder cancer by downregulating Wnt/beta-catenin signaling.
    J Biochem Mol Toxicol. 2021 May 31:e22835. doi: 10.1002/jbt.22835.
    >> Share


    J Bone Jt Infect

  64. STERN R, Roscoe C, Misch EA
    Mycobacterium bovis BCG osteoarticular infection complicating immune therapy for bladder cancer: a case report.
    J Bone Jt Infect. 2021;6:107-110.
    >> Share


    J BUON

  65. XU A, Yang GG, Zhang Y, Zhao ST, et al
    Heptaphylline suppresses the proliferation and migration of human bladder cancer cells via induction of intrinsic apoptosis, autophagy and inhibition of beta-catenin signalling pathway.
    J BUON. 2021;26:646.
    >> Share


    J Cancer Res Clin Oncol

  66. BASU M, Chatterjee A, Chakraborty B, Chatterjee E, et al
    High nuclear expression of HIF1alpha, synergizing with inactivation of LIMD1 and VHL, portray worst prognosis among the bladder cancer patients: association with arsenic prevalence.
    J Cancer Res Clin Oncol. 2021 Jun 2. pii: 10.1007/s00432-021-03661.
    >> Share


    J Clin Neurosci

  67. LIM JX, Chan SKS, Hwang PYK
    Trans-sulcal parafascicular approach to subcortical lesions.
    J Clin Neurosci. 2021;86:45-49.
    >> Share


    J Endourol

  68. MORELLI M, Baboudjian M, Vanacore D, Gondran-Tellier B, et al
    Early PDD Cystoscopy after BCG Induction for High-risk Non-Muscle Invasive Bladder Cancer Significantly Increased the Detection of BCG-refractory Tumors.
    J Endourol. 2021 Jun 9. doi: 10.1089/end.2021.0313.
    >> Share


    J Exp Clin Cancer Res

  69. PEIXOTO A, Ferreira D, Azevedo R, Freitas R, et al
    Glycoproteomics identifies HOMER3 as a potentially targetable biomarker triggered by hypoxia and glucose deprivation in bladder cancer.
    J Exp Clin Cancer Res. 2021;40:191.
    >> Share


    J Magn Reson Imaging

  70. CAI Q, Wen Z, Huang Y, Li M, et al
    Investigation of Synthetic Magnetic Resonance Imaging Applied in the Evaluation of the Tumor Grade of Bladder Cancer.
    J Magn Reson Imaging. 2021 Jun 3. doi: 10.1002/jmri.27770.
    >> Share


    J Manag Care Spec Pharm

  71. BEINFELD M, Atlas SJ, Touchette D, McKenna A, et al
    The effectiveness and value of nadofaragene firadenovec, oportuzumab monatox, and pembrolizumab for BCG-unresponsive non-muscle-invasive bladder cancer.
    J Manag Care Spec Pharm. 2021;27:797-804.
    >> Share


    J Nanosci Nanotechnol

  72. WANG L, Tao H, Li Z, Lei Y, et al
    Preparation of Composite Cypate Nanoparticles and Its Application in the Treatment of Pediatric Bladder Tumors.
    J Nanosci Nanotechnol. 2021;21:868-877.
    >> Share


    J Natl Cancer Inst

  73. APPLEMAN LJ
    Multifactorial, Biomarker-Based Predictive Models for Immunotherapy Response Enter the Arena.
    J Natl Cancer Inst. 2021;113:7-8.
    >> Share


    J Pers Med

  74. JUTTE H, Reike M, Wirtz RM, Kriegmair M, et al
    KRT20, KRT5, ESR1 and ERBB2 Expression Can Predict Pathologic Outcome in Patients Undergoing Neoadjuvant Chemotherapy and Radical Cystectomy for Muscle-Invasive Bladder Cancer.
    J Pers Med. 2021;11.
    >> Share


    J Urol

  75. ZHANG R, Zang J, Xie F, Zhang Y, et al
    Urinary Molecular Pathology for Patients with Newly Diagnosed Urothelial Bladder Cancer.
    J Urol. 2021 Jun 1:101097JU0000000000001878. doi: 10.1097/JU.0000000000001878.
    >> Share


    J Vasc Surg Cases Innov Tech

  76. PHAM STD, Lee A, Struminger JS, Belkoff KM, et al
    Mycotic infrarenal aortic aneurysm due to mycobacterium after intravesical treatment for bladder cancer.
    J Vasc Surg Cases Innov Tech. 2021;7:354-356.
    >> Share


    JCO Clin Cancer Inform

  77. NOONE AM, Lam CJK, Smith AB, Nielsen ME, et al
    Machine Learning Methods to Identify Missed Cases of Bladder Cancer in Population-Based Registries.
    JCO Clin Cancer Inform. 2021;5:641-653.
    >> Share


    Jpn J Clin Oncol

  78. ANNO T, Kikuchi E, Shigeta K, Ogihara K, et al
    Site-specific differences in survival among upper and lower tract urothelial carcinoma patients treated with radical surgery.
    Jpn J Clin Oncol. 2021;51:984-991.
    >> Share


    Lancet Oncol

  79. BALAR AV, Kamat AM, Kulkarni GS, Uchio EM, et al
    Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study.
    Lancet Oncol. 2021 May 26. pii: S1470-2045(21)00147.
    >> Share


    Mol Biol Rep

  80. EL-SHAL AS, Shalaby SM, Abouhashem SE, Elbary EHA, et al
    Urinary exosomal microRNA-96-5p and microRNA-183-5p expression as potential biomarkers of bladder cancer.
    Mol Biol Rep. 2021 Jun 4. pii: 10.1007/s11033-021-06451.
    >> Share


    Nat Commun

  81. BRISUDA A, Ho JCS, Kandiyal PS, Ng JT, et al
    Bladder cancer therapy using a conformationally fluid tumoricidal peptide complex.
    Nat Commun. 2021;12:3427.
    >> Share


    Oncoimmunology

  82. ZHOU L, Xu B, Liu Y, Wang Z, et al
    Tertiary lymphoid structure signatures are associated with survival and immunotherapy response in muscle-invasive bladder cancer.
    Oncoimmunology. 2021;10:1915574.
    >> Share


    Sci Rep

  83. LAI WH, Fang CY, Chou MC, Lin MC, et al
    Peptide-guided JC polyomavirus-like particles specifically target bladder cancer cells for gene therapy.
    Sci Rep. 2021;11:11889.
    >> Share


    Urol Oncol

  84. MOUSSA M, Chakra MA, Saad W, Dellis A, et al
    The role of 18F-FDG PET/CT scan compared to CT-scan alone for lymph node staging before radical cystectomy in patients with bladder cancer.
    Urol Oncol. 2021 May 29. pii: S1078-1439(21)00183.
    >> Share

  85. MATULEWICZ RS, Ravvaz K, Weissert JA, Porten S, et al
    Association of smoking status and recurrence of non-muscle invasive bladder cancer among patients managed with blue light cystoscopy.
    Urol Oncol. 2021 May 27. pii: S1078-1439(21)00185.
    >> Share

  86. STEINBERG RL, Packiam VT, Thomas LJ, Brooks N, et al
    Intravesical sequential gemcitabine and docetaxel versus bacillus calmette-guerin (BCG) plus interferon in patients with recurrent non-muscle invasive bladder cancer following a single induction course of BCG.
    Urol Oncol. 2021 Jun 3. pii: S1078-1439(21)00134.
    >> Share

  87. CLAPS F, Rai S, Mir MC, van Rhijn BWG, et al
    Prognostic value of preoperative albumin-to-fibrinogen ratio (AFR) in patients with bladder cancer treated with radical cystectomy.
    Urol Oncol. 2021 May 25. pii: S1078-1439(21)00184.
    >> Share


    Urologia

  88. SERRETTA V, Berardinis E, Simonato A, Guarneri A, et al
    A prospective observational study on oral administration of Ellagic Acid and Annona Muricata in patients affected by non-muscle invasive bladder cancer not undergoing maintenance after 6-week intravesical prophylaxis.
    Urologia. 2021 Jun 2:3915603211022285. doi: 10.1177/03915603211022285.
    >> Share


    Vaccines (Basel)

  89. KLINGER D, Hill BL, Barda N, Halperin E, et al
    Bladder Cancer Immunotherapy by BCG Is Associated with a Significantly Reduced Risk of Alzheimer's Disease and Parkinson's Disease.
    Vaccines (Basel). 2021;9.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016